You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Keynote

Showing 1 - 25 of 398
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hepatocellular Carcinoma Trial (Pembrolizumab)

Active, not recruiting
Has Results
  • Hepatocellular Carcinoma
  • Pembrolizumab
  • (no location specified)
Dec 15, 2022

Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma Trial (XNW5004, Pembrolizumab 25 mg/mL Solution for

Not yet recruiting
  • Carcinoma
  • +7 more
  • XNW5004
  • Pembrolizumab 25 mg/mL Solution for Injection
  • (no location specified)
Aug 31, 2023

Metastatic Castration-resistant Prostate Cancer Trial (Pembrolizumab, Enzalutamide)

Completed
  • Metastatic Castration-resistant Prostate Cancer
  • (no location specified)
Aug 16, 2022

Renal Cell Carcinoma Trial (Pembrolizumab)

Completed
Has Results
  • Renal Cell Carcinoma
  • Pembrolizumab
  • (no location specified)
Aug 17, 2022

Hepatocellular Carcinoma Trial (biological, drug, other)

Completed
Has Results
  • Hepatocellular Carcinoma
  • Pembrolizumab
  • +2 more
  • (no location specified)
Aug 30, 2022

Esophageal Carcinoma, Esophagogastric Junction Carcinoma Trial (pembrolizumab)

Completed
Has Results
  • Esophageal Carcinoma
  • Esophagogastric Junction Carcinoma
  • pembrolizumab
  • (no location specified)
Aug 18, 2022

Colorectal Carcinoma Trial (mFOLFOX6, FOLFIRI, pembrolizumab)

Active, not recruiting
Has Results
  • Colorectal Carcinoma
  • (no location specified)
Oct 28, 2022

Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial (pembrolizumab, cisplatin, 5-FU)

Completed
Has Results
  • Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • pembrolizumab
  • +3 more
  • (no location specified)
Jul 13, 2022

Emulation of KEYNOTE-189 Trial Using Electronic Health Records

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Metastatic Lung Cancer
  • Boston, Massachusetts
    Aetion
Jun 14, 2023

Renal Cell Carcinoma Trial (Pembrolizumab, Axitinib, Sunitinib)

Active, not recruiting
Has Results
  • Renal Cell Carcinoma
  • Pembrolizumab
  • +2 more
  • (no location specified)
Aug 17, 2022

Non-Small-Cell Lung Carcinoma Trial (biological, drug, dietary supplement)

Active, not recruiting
Has Results
  • Non-Small-Cell Lung Carcinoma
  • Pembrolizumab 200 mg
  • +7 more
  • (no location specified)
Aug 16, 2022

Ovarian Tumors Trial (Pembrolizumab)

Completed
Has Results
  • Ovarian Neoplasms
  • Pembrolizumab
  • (no location specified)
Feb 23, 2022

NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • pembrolizumab
  • +3 more
  • (no location specified)
Aug 18, 2022

Triple Negative Breast Cancer (TNBC) Trial (Pembrolizumab, Nab-paclitaxel, Paclitaxel)

Active, not recruiting
Has Results
  • Triple Negative Breast Cancer (TNBC)
  • Pembrolizumab
  • +5 more
  • (no location specified)
Jul 15, 2022

Colorectal Carcinoma Trial (Pembrolizumab)

Completed
Has Results
  • Colorectal Carcinoma
  • Pembrolizumab
  • (no location specified)
Mar 29, 2022

NSCLC Trial in Shanghai (Pembrolizumab, Paclitaxel, Nab-paclitaxel)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • Pembrolizumab
  • +4 more
  • Shanghai, China
    Zhongshan Hospital Fudan University
Aug 18, 2022

NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • pembrolizumab
  • +3 more
  • (no location specified)
Aug 18, 2022

Urothelial Cancer Trial (pembrolizumab)

Completed
Has Results
  • Urothelial Cancer
  • pembrolizumab
  • (no location specified)
Aug 18, 2022

Esophageal Carcinoma, Esophagogastric Junction Carcinoma Trial (pembrolizumab, paclitaxel, docetaxel)

Completed
Has Results
  • Esophageal Carcinoma
  • Esophagogastric Junction Carcinoma
  • pembrolizumab
  • +3 more
  • (no location specified)
May 5, 2022

NSCLC Trial (Pembrolizumab, Docetaxel)

Active, not recruiting
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Aug 18, 2022

Hodgkin Lymphoma Trial (pembrolizumab, brentuximab vedotin)

Active, not recruiting
  • Hodgkin Lymphoma
  • pembrolizumab
  • brentuximab vedotin
  • (no location specified)
Aug 18, 2022

Head and Neck Squamous Cell Cancer Trial (pembrolizumab, methotrexate, docetaxel)

Completed
Has Results
  • Head and Neck Squamous Cell Cancer
  • pembrolizumab
  • +3 more
  • (no location specified)
Aug 24, 2022

Lymphoma, B-Cell Trial in Japan (Pembrolizumab)

Active, not recruiting
  • Lymphoma, B-Cell
  • Nagoya, Aichi, Japan
  • +8 more
Aug 18, 2022

Metastatic Triple Negative Breast Cancer Trial (pembrolizumab, capecitabine, eribulin)

Completed
Has Results
  • Metastatic Triple Negative Breast Cancer
  • pembrolizumab
  • +4 more
  • (no location specified)
Nov 9, 2021

Hodgkin Lymphoma Trial (pembrolizumab)

Active, not recruiting
  • Hodgkin Lymphoma
  • pembrolizumab
  • (no location specified)
May 30, 2022